

# TRIOCHEM PRODUCTS LIMITED

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai,  
Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181  
E-mail: [info@amphray.com](mailto:info@amphray.com) Website: [www.triochemproducts.com](http://www.triochemproducts.com)  
Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 20241244 2024; 12<sup>th</sup> February 2025

To  
BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers, Dalal Street,  
Fort, Mumbai: 400 001.

Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held on Wednesday 12<sup>th</sup> February 2025

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements)  
Regulation, 2015

We would like to inform you that, pursuant to Notice of Board meeting dated 4<sup>th</sup> February 2025 the Board Meeting of the Company was held today Wednesday 12<sup>th</sup> February 2025 at 3.00 p.m. at 4<sup>th</sup> Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai: 400001, the registered office of the Company, In pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board has considered an approved the following:

1. The Board approved the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended on 31<sup>st</sup> December 2024, as reviewed by the Audit Committee, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
2. The Board noted and took on records the Limited Review Report for the quarter and nine months ended on 31<sup>st</sup> December 2024 submitted by the Statutory Auditors as placed before the Board.
3. The Board discussed and took note of the statement of deviation or variation in public issue, rights issue, preferential issue, etc. under Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 31<sup>st</sup> December 2024 as amended as per Circular No. CIR/CFD/CMD1/162/2019, dated 24<sup>th</sup> December 2019, duly reviewed by the Audit Committee along and the auditor's comments, that, The statement of Category wise variation is also not applicable as there has been no offer made by way of



# TRIOCHEM PRODUCTS LIMITED

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai,  
Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181  
E-mail: [info@amphray.com](mailto:info@amphray.com) Website: [www.triochemproducts.com](http://www.triochemproducts.com)  
Corporate Identity Number: L24249MH1972PLC015544



Public Issue, Rights Issue, Preferential Issue, etc., during the Quarter ended 31<sup>st</sup> December 2024.

4. Take notes on the compliance for the quarter ended 31<sup>st</sup> December 2025.
5. The board Meeting commenced at 3.00 p.m. and concluded at 3.45 p.m.

We wish to state that Mr. Ramu S. Deora (DIN 00312369) was the Chairperson of the Board meeting held on 12<sup>th</sup> February 2025 and the authorized director to sign and submit the Said Financial Result to the BSE Limited, in compliance with applicable provision of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.

You are requested to take note of the same.

Thanking you,  
Yours faithfully,  
For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA  
DIRECTOR  
DIN: 00312369  
Place: Mumbai

RAMU  
SITARAM  
DEORA

Digitally signed  
by RAMU  
SITARAM DEORA  
Date: 2025.02.12  
15:50:12 +05'30'



# Kanu Doshi Associates LLP

## Chartered Accountants

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,  
The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")

1. We have reviewed the accompanying statement of unaudited financial results of TRIOCHEM PRODUCTS LIMITED ("Company") for the quarter and nine months ended December 31, 2024 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time.
2. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind As 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP  
Chartered Accountants  
Firm Registration No: 104746W/W100096



Kunal Vakharia  
Partner  
Membership No: 148916  
UDIN: 25148916BMKNHG4085



Place: Mumbai  
Date: February 12, 2025

Mumbai Office : 203, The Summit, Hanuman Road, Western Express Highway, Vile Parle (E), Mumbai - 400 057 T : 022-2615 0100  
Pune Office : 109, Sohrab Hall, 21 Sassoon Road, Opp. Jehangir Hospital, Pune - 411001 T : 020-4906 7177  
E : info@kdg.co.in W : www.kdg.co.in. FRN : 104746W/W100096

6



**TRIOCHEM PRODUCTS LIMITED**  
**MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS**

Registered Office : 4<sup>th</sup> Floor, Sambhava Chambers, Sir P. M. Road, Fort, Mumbai, Maharashtra,  
 PIN - 400001, Telephone : (0 91 (22) 2266 3150 Fax: 00 91 (22) 2202 9657  
 E-mail : info@amphray.com Website : www.triochemproducts.com  
 Corporate Identity Number : L24249MH1972PLC015544



**TRIOCHEM PRODUCTS LIMITED**  
 Registered Office : Sambhava Chamber, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001.  
 Website : www.triochemproducts.com  
 CIN : L24249MH1972PLC015544

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024**

Sr. No.	Particulars	(Rs in Lakh) Except EPS					
		Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-24 (Unaudited)	30-Sep-24 (Unaudited)	31-Dec-23 (Unaudited)	31-Dec-24 (Unaudited)	31-Dec-23 (Unaudited)	31-Mar-24 (Audited)
1	<b>Income</b>						
	(a) Revenue from Operations	-	-	-	-	-	-
	(b) Other Income	35.85	26.69	3.50	72.54	22.73	102.96
	<b>Total Income From Operations</b>	<b>35.85</b>	<b>26.69</b>	<b>3.50</b>	<b>72.54</b>	<b>22.73</b>	<b>102.96</b>
	<b>Expenses</b>						
	(a) Cost of Materials Consumed	-	-	-	-	-	0.01
	(b) Purchase of stock in trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employees Benefit Expenses	29.53	14.71	11.23	44.24	34.20	97.29
	(e) Finance Costs	-	-	-	-	-	-
	(f) Depreciation and Amortisation Expenses	3.84	1.94	2.26	5.78	6.76	8.97
	(g) Other Expenditure	29.39	14.95	11.83	44.32	44.12	64.04
	<b>Total expenses</b>	<b>62.76</b>	<b>31.58</b>	<b>25.32</b>	<b>94.34</b>	<b>85.08</b>	<b>120.31</b>
	<b>Profit before exceptional items and tax</b>	<b>(16.91)</b>	<b>(4.89)</b>	<b>(21.82)</b>	<b>(21.80)</b>	<b>(62.35)</b>	<b>(17.35)</b>
4	Exceptional items (refer Note 4)	-	-	-	-	(115.65)	(115.65)
5	<b>Profit/ (Loss) before tax</b>	<b>(16.91)</b>	<b>(4.89)</b>	<b>(21.82)</b>	<b>(21.80)</b>	<b>(178.00)</b>	<b>(133.00)</b>
6	<b>Tax Expense</b>						
	(a) Current tax (Refer Note 5)	(22.33)	-	-	(22.33)	-	11.86
	(b) Deferred tax	(3.41)	(1.23)	(1.38)	(4.64)	(44.23)	(43.53)
	<b>Total tax expenses</b>	<b>(25.74)</b>	<b>(1.23)</b>	<b>(1.38)</b>	<b>(26.97)</b>	<b>(44.23)</b>	<b>(31.67)</b>
7	<b>Net Profit/ (Loss) for the period</b>	<b>8.83</b>	<b>(3.66)</b>	<b>(20.44)</b>	<b>5.17</b>	<b>(133.77)</b>	<b>(101.33)</b>
	<b>Other Comprehensive Income (Net of Taxes)</b>						
	(A)(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	(B)(i) Item that will not be reclassified to profit or loss	(40.70)	39.34	214.88	(1.36)	358.07	455.63
	(ii) Income tax relating to items that will not be reclassified to profit or loss	8.73	(17.03)	(24.62)	(8.30)	(40.96)	(52.00)
	<b>Total other Comprehensive Income (net of taxes)</b>	<b>(31.97)</b>	<b>22.31</b>	<b>190.26</b>	<b>(9.66)</b>	<b>317.11</b>	<b>403.63</b>
9	<b>Total Comprehensive Income for the period</b>	<b>(23.14)</b>	<b>18.65</b>	<b>169.82</b>	<b>(4.49)</b>	<b>183.34</b>	<b>302.30</b>
10	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
11	Other equity as per Balance Sheet of previous accounting year						1,437.52
12	Earnings per equity share (EPS) (of Rs 10/- each) (not annualised)						
	Basic / Diluted EPS (in Rs.)	3.60	(1.49)	(8.34)	2.11	(54.60)	(41.36)



**TRIOCHEM PRODUCTS LIMITED**

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir P M Road, Fort, Mumbai, Maharashtra

PIN: 400001 Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: [info@amphray.com](mailto:info@amphray.com) Website: [www.triochemproducts.com](http://www.triochemproducts.com)

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED	
Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.	
Website: <a href="http://www.triochemproducts.com">www.triochemproducts.com</a>	
CIN : L24249MH1972PLC015544	
<b>STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024</b>	
Notes:	
1)	The above unaudited standalone financial results of the Company for the quarter and nine months ended 31st December 2024 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.02.2025. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.
2)	The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India, as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
3)	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
4)	During the previous year, the company had complied with circular no. 16/2023-Cus dated 7th June 2023 issued by The Central Board of Indirect taxes and Customs Drawback division for compliance with the 'pre-import condition for payment of IGST and interest thereon for imports made under Advance Authorization on or after 13th October 2017 till 9th January 2019 on which IGST exemption had been availed. As per the circular the company was non-compliant with the 'pre-import' conditions as defined in the revised circular no. 16/2023-Cus dated 7th June 2023 due to which the company was liable to pay Rs. 259.87 lakhs including interest. The Company had claimed the credit of IGST paid and the interest portion amounting to Rs. 115.65 lakhs had been shown under Exceptional items.
5)	The amount appearing in Current Tax for the current quarter represents reversal of excess tax provision of earlier years.
6)	The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
FOR TRIOCHEM PRODUCTS LIMITED	
9 _____ RAMU S. DEORA CHAIRPERSON DIN : 00312369	
Place: Mumbai	
Dated: 12th February, 2025	



5



**TRIOCHEM PRODUCTS LIMITED**

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai, Maharashtra,  
PIN: 400001, Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED							
Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001							
website: www.triochemproducts.com							
CIN: L24249MH1972PLC015544							
(Rs. in lakhs) Except EPS							
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024							
Sr No	Particulars	Quarter Ended			Half Year Ended		For the Year Ended on 31-Mar-24 Audited
		31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Total Income from operations	45.85	26.69	3.50	72.54	22.73	102.96
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	(16.91)	(4.89)	(21.82)	(21.80)	(62.35)	(17.35)
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	(16.91)	(4.89)	(21.82)	(21.80)	(178.00)	(133.00)
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	8.83	(3.66)	(20.44)	5.17	(135.77)	(101.33)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	(31.97)	22.31	190.26	(9.66)	317.11	403.63
6	Equity share capital (Face value Rs. 10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
7	Other Equity						1,437.52
8	Earnings per share (of Rs 10/- each) (for continuing and discontinued operations)						
	a) Basic (not annualized)	3.60	(1.49)	(8.34)	2.11	(54.60)	(41.36)
	b) Diluted (not annualized)	3.60	(1.49)	(8.34)	2.11	(54.60)	(41.36)

Notes:

- The above unaudited standalone financial results of the Company for the quarter and nine months ended 31st December 2024 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.02.2025. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.
- The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India, as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- The Company operates in single segment only, i.e. chemical and pharmaceuticals, therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- During the previous year, the company had complied with circular no. 16/2023-Cus dated 7th June 2023 issued by The Central Board of Indirect taxes and Customs Drawback division for compliance with the pre-import condition for payment of IGST and interest thereon for imports made under Advance Authorization on or after 13th October 2017 till 9th January 2019 on which IGST exemption had been availed. As per the circular the company was non-compliant with the 'pre-import' conditions as defined in the revised circular no. 16/2023-Cus dated 7th June 2023 due to which the company was liable to pay Rs. 259.87 lakhs including interest. The Company had claimed the credit of IGST paid and the interest portion amounting to Rs. 115.65 lakhs had been shown under exceptional items.
- The amount appearing in Current Tax for the current quarter represents reversal of excess tax provision of earlier years.
- The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
- The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website, www.bseindia.com and on the Company's website www.triochemproducts.com.

FOR TRIOCHEM PRODUCTS LIMITED



  
**RAMU S. DEORA**  
 CHAIRPERSON  
 DIN: 00312369

Place: Mumbai

Dated: 12th February, 2025



Date & Time of Download : 12/02/2025 16:02:47

**BSE ACKNOWLEDGEMENT**

<b>Acknowledgement Number</b>	9010526
<b>Date and Time of Submission</b>	2/12/2025 3:58:06 PM
<b>Scripcode and Company Name</b>	512101 - TRIOCHEM PRODUCTS LTD.
<b>Subject / Compliance Regulation</b>	Board Meeting Outcome for Outcome Of The Board Meeting Held On Wednesday 12Th February 2025
<b>Submitted By</b>	Puran Jaykisan Parmar
<b>Designation</b>	Designated Officer for Filing

**Disclaimer** : - Contents of filings has not been verified at the time of submission.